[go: up one dir, main page]

PE20010692A1 - MODIFIED PEPTIDES AND PEPTIDOMIMETICS FOR USE IN IMMUNOTHERAPY - Google Patents

MODIFIED PEPTIDES AND PEPTIDOMIMETICS FOR USE IN IMMUNOTHERAPY

Info

Publication number
PE20010692A1
PE20010692A1 PE2000001107A PE0011072000A PE20010692A1 PE 20010692 A1 PE20010692 A1 PE 20010692A1 PE 2000001107 A PE2000001107 A PE 2000001107A PE 0011072000 A PE0011072000 A PE 0011072000A PE 20010692 A1 PE20010692 A1 PE 20010692A1
Authority
PE
Peru
Prior art keywords
amino acids
alkyl
substitution
ser
amida
Prior art date
Application number
PE2000001107A
Other languages
Spanish (es)
Inventor
Anna Maria Helena Boots
Cornelis Marius Timmers
Staveren Catherina Joanna Van
Galen Philippus Johannes Marie Van
Ronald Marcellus Alphonsun Knegtel
Andreas Martinus Maria Miltenburg
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of PE20010692A1 publication Critical patent/PE20010692A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rehabilitation Therapy (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UN PEPTIDO MODIFICADO DERIVADO DE H-ARG-SER-PHE-THR-LEU-ALA-SER-SER-GLU-THR-GLY-VAL-GLY-OH DE FORMULA Q-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12-A13-Z; DONDE A1 A A13 SON AMINOACIDOS; Q ES H; Z ES OH; CARACTERIZADO PORQUE 1 A 6 MODIFICACIONES SON GRUPOS a, b, c; CONSISTEN EN: a)SUSTITUCION DE 1-6 AMINOACIDOS EN A1 A A13 POR AMINOACIDOS NO NATURALES O ß-AMINOACIDOS; b)SUSTITUCION DE UNO O MAS ENLACES AMIDA POR ENLACES AMIDA REDUCIDOS O ISOESTERES DE ETILENO; c)SUSTITUCION EN Q Y/O Z; d)SUSTITUCION POR AMINOACIDOS NATURALES HASTA 6 MODIFICACIONES; Q ES H, ALQUILO C1-C6, FORMILO, ALQUILCARBONILO C1-C6, CARBOXIALQUILO C1-C6, ALQUILOXICARBONILO C1-C6; ALQUENILOXICARBONILO C2-C6, ENTRE OTROS; Z ES OR; R ES H, ALQUILO C1-C6, ALQUENILO C2-C6, ENTRE OTROS; R1 Y R2 SON H, ALQUILO C1-C6, ARIL C6-C14-ALQUILO C1-C6; Q Y Z JUNTOS COMPRENDEN EN SUMA HASTA 10 AMINOACIDOS UBICADOS CONTIGUOS A LA POSICION A1, A13. EL USO DEL PEPTIDO INDUCE TOLERANCIA DE CELULAS T ESPECIFICAS PARA UN AUTOANTIGENO EN PACIENTES QUE SUFREN TRASTORNOS AUTOINMUNES COMO ARTRITISREFERS TO A MODIFIED PEPTIDE DERIVED FROM H-ARG-SER-PHE-THR-LEU-ALA-SER-SER-GLU-THR-GLY-VAL-GLY-OH OF FORMULA Q-A1-A2-A3-A4-A5 -A6-A7-A8-A9-A10-A11-A12-A13-Z; WHERE A1 TO A13 ARE AMINO ACIDS; Q IS H; Z IS OH; CHARACTERIZED BECAUSE 1 TO 6 MODIFICATIONS ARE GROUPS a, b, c; CONSIST OF: a) SUBSTITUTION OF 1-6 AMINO ACIDS IN A1 TO A13 BY NON-NATURAL AMINO ACIDS OR ß-AMINO ACIDS; b) SUBSTITUTION OF ONE OR MORE AMIDA LINKS BY REDUCED AMIDA LINKS OR ETHYLENE ISOSTERS; c) SUBSTITUTION IN Q AND / OR Z; d) SUBSTITUTION BY NATURAL AMINO ACIDS UP TO 6 MODIFICATIONS; Q IS H, C1-C6 ALKYL, FORMYL, C1-C6 ALKYLCARBONYL, C1-C6 CARBOXIALKYL, C1-C6 ALKYLOXYCARBONYL; C2-C6 ALKENYLOXYCARBONYL, AMONG OTHERS; Z IS OR; R IS H, C1-C6 ALKYL, C2-C6 ALKYL, AMONG OTHERS; R1 AND R2 ARE H, C1-C6 ALKYL, C6-C14 ARYL-C1-C6 ALKYL; Q AND Z TOGETHER INCLUDE UP TO 10 AMINO ACIDS LOCATED NEXT TO POSITION A1, A13. THE USE OF THE PEPTIDE INDUCES TOLERANCE OF SPECIFIC T-CELLS FOR SELF-ANTIGENE IN PATIENTS SUFFERING FROM AUTOIMMUNE DISORDERS SUCH AS ARTHRITIS

PE2000001107A 1999-10-18 2000-10-17 MODIFIED PEPTIDES AND PEPTIDOMIMETICS FOR USE IN IMMUNOTHERAPY PE20010692A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99203427 1999-10-18

Publications (1)

Publication Number Publication Date
PE20010692A1 true PE20010692A1 (en) 2001-07-06

Family

ID=8240756

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000001107A PE20010692A1 (en) 1999-10-18 2000-10-17 MODIFIED PEPTIDES AND PEPTIDOMIMETICS FOR USE IN IMMUNOTHERAPY

Country Status (23)

Country Link
EP (1) EP1226167A1 (en)
JP (1) JP2003512388A (en)
KR (1) KR20020047245A (en)
CN (1) CN1379786A (en)
AR (1) AR026068A1 (en)
AU (1) AU780238B2 (en)
BR (1) BR0014803A (en)
CA (1) CA2386398A1 (en)
CO (1) CO5271650A1 (en)
CZ (1) CZ20021356A3 (en)
HK (1) HK1046693A1 (en)
HU (1) HUP0203504A3 (en)
IL (1) IL148778A0 (en)
MX (1) MXPA02003520A (en)
NO (1) NO20021763D0 (en)
NZ (1) NZ518256A (en)
PE (1) PE20010692A1 (en)
PL (1) PL354590A1 (en)
RU (1) RU2002113107A (en)
SK (1) SK6842002A3 (en)
TR (1) TR200201036T2 (en)
WO (1) WO2001029081A1 (en)
ZA (1) ZA200202577B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002951212A0 (en) * 2002-09-04 2002-09-19 Monash University A method of modulating cellular activity and molecules for use therein
AU2007235305A1 (en) * 2006-04-06 2007-10-18 Purdue Research Foundation Derivatization-enhanced analysis of amino acids and peptides
EP2114462B1 (en) * 2006-12-21 2013-06-05 Universite De Geneve Compounds for fluorescence imaging
EP2245459A1 (en) 2008-01-23 2010-11-03 Herlev Hospital Ykl-40 as a general marker for non-specific disease
US8580520B2 (en) 2008-09-15 2013-11-12 Herlev Hospital YKL-40 as a marker for gastrointestinal cancers
WO2016073949A1 (en) 2014-11-07 2016-05-12 Kineta Three, Llp Modifications and uses of conotoxin peptides
EP3466963A1 (en) * 2017-10-05 2019-04-10 Suigeneris Farmacosmetics, S.L. Anticancer peptides and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL115744A (en) * 1994-10-27 2000-07-16 Akzo Nobel Nv Peptides comprising a subsequence of human cartilage glycoprotein - 39
TW575583B (en) * 1996-04-24 2004-02-11 Akzo Nobel Nv Novel peptides suitable for use in antigen specific immunosuppressive therapy
WO1997046578A1 (en) * 1996-06-07 1997-12-11 Zeneca Limited Peptide derivatives
IL122233A (en) * 1996-12-06 2001-04-30 Akzo Nobel Nv Method of preparing cell surface monolonal antibodies and pharmaceutical compositions and diagnostic reagents containing them

Also Published As

Publication number Publication date
AR026068A1 (en) 2002-12-26
CA2386398A1 (en) 2001-04-26
ZA200202577B (en) 2003-09-23
BR0014803A (en) 2002-06-11
JP2003512388A (en) 2003-04-02
NO20021763L (en) 2002-04-15
KR20020047245A (en) 2002-06-21
AU780238B2 (en) 2005-03-10
PL354590A1 (en) 2004-01-26
IL148778A0 (en) 2002-09-12
HUP0203504A2 (en) 2003-04-28
EP1226167A1 (en) 2002-07-31
NZ518256A (en) 2004-01-30
CN1379786A (en) 2002-11-13
WO2001029081A1 (en) 2001-04-26
MXPA02003520A (en) 2002-08-20
AU1139601A (en) 2001-04-30
HUP0203504A3 (en) 2005-03-29
HK1046693A1 (en) 2003-01-24
CO5271650A1 (en) 2003-04-30
NO20021763D0 (en) 2002-04-15
RU2002113107A (en) 2004-01-10
CZ20021356A3 (en) 2002-07-17
TR200201036T2 (en) 2002-08-21
SK6842002A3 (en) 2002-09-10

Similar Documents

Publication Publication Date Title
PE20120914A1 (en) GIP RECEIVER ACTIVE GLUCAGON COMPOUNDS
PE20211992A1 (en) PROCESS TO PREPARE A GIP / GLP1 DUAL AGONIST
BR0114630A (en) Growth Hormone Secretagogues
AR065349A1 (en) GLUCAGON / GLP-1 RECEIVER COAGONISTS
ES2194224T3 (en) USE OF GLP-1 ANALOGS AND DERIVATIVES PERIPHERALLY ADMINISTERED FOR THE REGULATION OF OBESITY.
AR036196A1 (en) MULTIMERIC CONTRACT AGENTS DIRECTED TO PEPTIDES
MX9500072A (en) Compounds having growth hormone releasing properties.
CY1113850T1 (en) NEW INSULIN PRODUCERS
MX9305077A (en) POLYMERIC AMMONIUM SALTS, RETICULATED AND PHARMACEUTICAL COMPOSITIONS INCLUDING THEM.
PE20010692A1 (en) MODIFIED PEPTIDES AND PEPTIDOMIMETICS FOR USE IN IMMUNOTHERAPY
ES2178000T3 (en) COMPOSITIONS AND METHODS TO TREAT INFECTIONS USING INDOLICIDINE ANALOGS.
BRPI0517493A (en) isolated polynucleotide, expression vector promoter, host cell and use of a polynucleotide
MX9302475A (en) POLYPEPTIDE OF NON-NATURAL ORIGIN THAT HAS THE ACTIVITY OF THE RECOMBINANT FACTOR OF STIMULATION OF THE NEU RECEPTOR AND PROCESS FOR THE PRODUCTION OF MY MO.
ES2172937T3 (en) 21-HYDROXI-6,19-OXIDOPROGESTERONE (21OH-6OP) AS A MEDICINAL PRODUCT TO TREAT THE EXCESS OF GLUCOCORTICOIDS.
AR008094A1 (en) PROCESS FOR THE SYNTHESIS OF A SYNTHETIC POLYPEPTIDE ANALOGED TO PARATHYROID HORMONE OR PEPTIDE RELATED TO PARATHYROID HORMONE AND PROCESS FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION.
TW200517400A (en) Antagonistic analogs of GH-RH (2003)
PE20030974A1 (en) CORTICOTROPIN RELEASING FACTOR RECEPTOR 2 AGONISTS
MX2024000233A (en) Regenerative polypeptides and uses thereof.
AR075933A1 (en) POLYPEPTIDE AND IMMUNIZATION COMPOSITIONS CONTAINING GRAM POSITIVE POLYPEPTIDES AND METHODS OF USE
PE20040705A1 (en) STICKED T20 POLYPEPTIDE
TW200611706A (en) Cytotoxic t lymphocyte
ES2114555T3 (en) NEW RECOMBINED HUMAN GAMMA INTERFERON.
AR044852A1 (en) A PHARMACEUTICAL COMPOSITION FOR PARENTERAL ADMINISTRATION THAT INCLUDES A SOMATOSTATINE ANALOG
RU2006115606A (en) USE OF SOMATOSTATIN OR ONE OF ITS ANALOGUES FOR PREPARATION OF THE MEDICINE FOR THE REGULATION OF THE FOLICULAR RESERVE OF THE OVARIES IN WOMEN WHO DOES NOT HAVE MENOPAUSE
SI1442059T1 (en) Analogs of human growth hormone-releasing hormone, their preparation and use

Legal Events

Date Code Title Description
FD Application declared void or lapsed